A literature review provided new insight into the clinical neurocognitive profile in major depressive disorder (MDD) and its relationship to cognitive deficits.
Potentiating current antidepressant treatment is much needed. Based on animal studies, caffeine may augment the effects of currently available antidepressants.
Repetitive transcranial magnetic stimulation (rTMS) is a tool that can be used to administer treatment to neuropsychiatric disorders such as major depressive disorder (MDD).
A high dose of intermittent theta-burst stimulation with functional-connectivity-guided targeting outperformed sham stimulation for treatment-resistant depression.
Antidepressant outcomes to repetitive transcranial magnetic stimulation (rTMS) are better when stimulation is serendipitously delivered to the prefrontal cortex.
rTMS treatment for Major Depressive Disorder MDD involves stimulation of the dorsolateral prefrontal cortex which plays an important role in cognitive function and mood.
Promising studies using repetitive T to help veterans and active-duty service members living with depression, post-traumatic stress disorder (PTSD), and other lasting consequences of concussion.
Repetitive transcranial magnetic stimulation (rTMS) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression since 2008.